Risk and prognostic factors of breast cancer with liver metastases

Source : https://link.springer.com/article/10.1186/s12885-021-07968-5

Background Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of...

The Exciting New Field of HER2-Low Breast Cancer Treatment

Source : https://www.mdpi.com/2072-6694/13/5/1015

Since human epidermal growth factor receptor-2 (HER2) characterization, going through clinical research and regulatory approval of HER2-targeted therapies, much has elapsed and is still unfolding. Hitherto, only breast cancer (BC)...

Liquid Biopsy: New Tool to Overcome CDKi Resistance Mechanism in Luminal Metastatic Breast Cancer

Source : https://www.preprints.org/manuscript/202103.0063/v1

Breast cancer is the most commonly diagnosed cancer in women worldwide. Approximately, 70 % of breast cancer patients express hormone receptors (HR) (Luminal subtype). Adjuvant endocrine treatments are the standard...

CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies

Source : https://www.futuremedicine.com/doi/full/10.2217/fon-2020-1264

cookie policy. ×

Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer

Source : https://cancerres.aacrjournals.org/content/81/4_Supplement/GS1-01

Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas Background monarchE is a phase 3, open-label study evaluating abemaciclib combined with endocrine therapy (ET) compared...